Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle

NCT05856136 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.

Interventions

  • DRUG Fentanyl Injection

Study Locations (1)

Minnesota

  • Mayo Clinic Minnesota — Rochester

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2023-06-19
Est. Completion 2026-06-01
Phase Phase 4

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05856136

The ClinicalTrials.gov registry entry for NCT05856136 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Respiratory Complication appearing as the primary indexed condition, and to 1 intervention — of which Fentanyl Injection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05856136 reports 1 study location spanning 1 distinct geographic area — top geographies include Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05856136 about?

NCT05856136 is a clinical study titled "A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle". The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.

What is the current status of trial NCT05856136?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2023-06-19. Estimated completion is 2026-06-01.

What conditions does trial NCT05856136 study?

This clinical trial studies the following conditions: Respiratory Complication, Respiratory Function Loss. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05856136?

The interventions under investigation include: Fentanyl Injection (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05856136?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05856136 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial